BCL2 and hepatocellular carcinoma: “In vivo” studies also demonstrated that EGCG could modulate miRNAs in cancers such as hepatocellular carcinoma and gastric cancer, targeting critical genes like c-Kit, Bcl2, E2F, and RAS.